Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) today announced
that The Helen F. Graham Cancer Center associated with Christiana Care
Health System, a screening site for the International Early Lung Cancer
Program (I-ELCAP), will recruit a cohort of patients diagnosed with lung
cancer to participate in the final stage of the Phase II pilot study of
the investigational CyPath® assay, an early-stage diagnostic test for
lung cancer.
“Running our diagnostic test on a control group of patients who are
known to have lung cancer but have not yet started therapy will provide
the final data we need to complete the pilot phase of our study,” said
Biomoda President John Cousins. “Christiana Care is a national role
model for both patient care and cancer research. We could not ask for a
better partner.”
Dr. Thomas Bauer, chief of thoracic surgery at Christiana Care’s Helen
F. Graham Cancer Center, is the Principal Investigator (PI) for the
Biomoda study. Bauer has led several lung and esophageal cancer studies
and heads up Christiana’s participation in the I-ELCAP. Christiana
Care’s Institutional Review Board reviewed the Biomoda study protocol to
ensure compliance with scientific, regulatory and ethical standards.